BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32350192)

  • 1. Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors.
    Matsuzu K; Sugino K; Masudo K; Mori K; Ono R; Yamazaki H; Masaki C; Akaishi J; Kiyomi Yamada H; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
    Endocr J; 2020 Aug; 67(8):869-876. PubMed ID: 32350192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
    Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
    Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
    Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
    Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
    Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
    Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
    Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
    Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e457-65. PubMed ID: 31665318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papillary thyroid carcinoma presenting as a primary renal tumor with multiple pulmonary and bone metastases: a case report.
    Gezer E; Selek A; Tarkun İ; Cantürk Z; Çetinarslan B
    J Med Case Rep; 2019 Apr; 13(1):95. PubMed ID: 31003598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.
    Zambeli-Ljepović A; Wang F; Dinan MA; Hyslop T; Roman SA; Sosa JA; Scheri RP
    J Surg Res; 2019 Nov; 243():189-197. PubMed ID: 31185435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AND DISTANT METASTASES.
    Hirsch D; Levy S; Tsvetov G; Gorshtein A; Slutzky-Shraga I; Akirov A; Robenshtok E; Shimon I; Benbassat CA
    Endocr Pract; 2017 Oct; 23(10):1193-1200. PubMed ID: 28704099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
    Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer.
    Nylén C; Eriksson FB; Yang A; Aniss A; Turchini J; Learoyd D; Robinson BG; Gill AJ; Clifton-Bligh RJ; Sywak MS; Glover AR; Sidhu SB
    Am J Surg; 2021 May; 221(5):886-892. PubMed ID: 32878695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer.
    Wang X; Zhu J; Li Z; Wei T
    PLoS One; 2020; 15(6):e0234843. PubMed ID: 32542018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer.
    Genpeng L; Jianyong L; Jiaying Y; Ke J; Zhihui L; Rixiang G; Lihan Z; Jingqiang Z
    Medicine (Baltimore); 2018 Feb; 97(5):e9619. PubMed ID: 29384841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.